You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • O13 Innate immunity transcriptional profiles as potential predictive biomarkers for treatment response in systemic lupus erythematosus: Insights from a longitudinal study

Article Text

Article menu

Download PDFPDF

Oral Presentations
O13 Innate immunity transcriptional profiles as potential predictive biomarkers for treatment response in systemic lupus erythematosus: Insights from a longitudinal study
  1. Panagiotis Garantziotis1,2,
  2. Georgia-Savina Moysidou1,
  3. Stavros Doumas3,
  4. Dionysis Nikolopoulos1,
  5. George Sentis1,
  6. Ricardo Grieshaber-Bouyer2,
  7. Myrto Nikoloudaki4,
  8. Dimitra Nikoleri4,
  9. Styliani Polia4,
  10. Anastasia Filia1,
  11. Antonis Fanouriakis1,
  12. George Bertsias4 and
  13. Dimitrios T Boumpas1
  1. 1School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
  2. 2Dept. of Internal Medicine 3-Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Germany
  3. 3Dept. of Medicine, MedStar Georgetown University Hospital, Washington, DC, USA
  4. 4Rheumatology, Clinical Immunology and Allergy, University of Crete School of Medicine, Iraklio, Crete, Greece

Abstract

Background Systemic Lupus Erythematosus (SLE) is a prototypic, systemic autoimmune disease that can affect many organs. Current treatment of SLE is largely empirical, while the existing immunosuppressive treatments fail to induce remission in over 40% of patients.

Methods Whole blood transcriptome samples were obtained from 95 patients with moderate to severe SLE at baseline, 1 month and 6 months after initiation of treatment with cytotoxic agents (cyclophosphamide, mycophenolate mofetil), mycophenolate mofetil/anti-CD40 antibody, rituximab or belimumab. Disease activity was assessed using the SLEDAI-2K. Response to treatment was defined as achievement of Low Disease Activity State (LLDAS) or remission at 6 months. Differentially expressed genes (DEGs) were identified using the DEseq2. Weighted correlation network analysis (WGCNA) was applied to detect modules of co-expressed transcripts. Abundances of cell types were assessed by CIBERSORTx.

Results 95 patients were enrolled in our study. Most of the patients were women (93.7%) with a mean [SD] age at SLE diagnosis of 42.9 [13.6] years and a mean disease duration [SD] at sampling of 5.1 [7.2] years. Cyclophosphamide was the most frequently used immunosuppressive agent (n=46), followed by belimumab (n=24) and rituximab (n=21). 43 patients responded to treatment. Transcriptional disturbances related to type I interferon signaling (p=0.04, r= 0.15) and leukocyte chemotaxis (p=0.005, r=0.21) positively correlated with response to treatment at 6 months. Enrichment of processes linked to complement activation and PI3KK/Akt pathway distinguishes active Lupus Nephritis (LN) responders from LN non-responders at baseline. Gene expression signatures indicative of cell cycle checkpoint regulation and humoral immunity emerged as potential determinants of resistant disease 6 months after treatment initiation. Marked reduction in the naïve B cell compartment uniquely characterized successful response induction, while the neutrophilic fraction exhibited a statistically significant reduction upon treatment, irrespective of the 6-month outcome.

Conclusions Baseline transcriptional signatures related to innate immunity correlated with 6-month response to treatment in SLE. Disturbances linked to cell cycle regulation decisively shaped the transcriptional landscape of ‘resistant’ disease.

Acknowledgements This work was supported by grants from EU (SYSCID grant agreement number 733100), ERC (LUPUSCARE grant agreement number 742390), FOREUM all to DTB.

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ .

https://doi.org/10.1136/lupus-2024-el.23

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.